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Abstract
Introduction: The success of HIV treatment programmes globally has resulted in children with perinatally acquired HIV reaching
adolescence in large numbers. The number of adolescents living with HIV is growing further due to persisting high HIV incidence
rates among adolescents in low- and middle-income settings, particularly in sub-Saharan Africa. Although expanding access to HIV
viral load monitoring is necessary to achieve the 90-90-90 targets across the HIV care continuum, implementation is incomplete.
We discuss the rationale for prioritizing viral load monitoring among adolescents and the associated challenges.
Discussion: Adolescents with HIV are a complex group to treat successfully due to extensive exposure to antiretroviral ther-
apy for those with perinatally acquired HIV and the challenges in sustained medication adherence in this age group. Given the
high risk of treatment failure among adolescents and the limited drug regimens available in limited resource settings, HIV viral
load monitoring in adolescents could prevent unnecessary and costly switches to second-line therapy in virologically sup-
pressed adolescents. Because adolescents living with HIV may be heavily treatment experienced, have suboptimal treatment
adherence, or may be on second or even third-line therapy, viral load testing would allow clinicians to make informed decisions
about increased counselling and support for adolescents together with the need to maintain or switch therapeutic regimens.
Conclusions: Given scarce resources, prioritization of viral load testing among groups with a high risk of virological failure
may be required. Adolescents have disproportionately high rates of virological failure, and targeting this age group for viral
load monitoring may provide valuable lessons to inform broader scale-up.
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1 | INTRODUCTION
The numbers of adolescents living with HIV has increased
globally by 30% since 2005 [1]. The paediatric HIV epidemic
is maturing, with increasing numbers of children living into
adolescence and young adulthood due to the scale-up of
antiretroviral therapy (ART), and HIV-infected children with
slow disease progression presenting to health services for the
first time in adolescence [2,3]. The persisting high incidence of
HIV among adolescents in low and middle-income settings
(LMICs), particularly among young women and girls, is also a
significant contributor to the increase in numbers of adoles-
cents living with HIV over the past decade. HIV is the second
biggest cause of death among adolescents globally, and
accounts for a substantial proportion of deaths in sub-Saharan
Africa [4]. Notably, HIV-related deaths among adolescents
have risen during a period in which there has been a signifi-
cant decline in HIV-related mortality among other age groups
[5].
HIV viral load (VL) testing allows accurate monitoring of
antiretroviral treatment and detection of virological failure.
Expanding access to VL monitoring is necessary to achieve the
ambitious UNAIDS treatment target that stipulates that 90%
that those on ART should have durable viral suppression.
Universal access to HIV VL testing has yet to be achieved
however. We discuss the rationale for prioritizing VL monitor-
ing among adolescents.
2 | THE STATE OF THE ADOLESCENT
HIV EPIDEMIC
An estimated 1.8 million adolescents between 10 and
19 years old were living with HIV in 2015, an increase of 28
per cent since 2005 [6]. The majority of these adolescents live
in resource-limited settings, 82% in sub-Saharan Africa, and
nearly half of the estimated numbers of adolescents living
with HIV are in five countries, India, Kenya, Nigeria, South
Africa and Tanzania [4,7]. This growing cohort of ado-
lescents comprises of two groups: those with perinatally
acquired infection born before widely available prevention of
mother-to-child transmission (PMTCT) who are surviving into
Marcus R et al. Journal of the International AIDS Society 2017, 20(S7):e25002
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25002/full | https://doi.org/10.1002/jia2.25002
37
adolescence and young adulthood, and those with largely
sexually acquired new infections [8]. The numbers of children
infected with HIV is declining due to the concerted
global effort of PMTCT. The use of antiretroviral therapy as
part of PMTCT programmes has averted 350,000 new paedi-
atric HIV infections, with a remarkable reduction in the annual
number of new infections amongst children by 70% since
2001 [9].
Children with perinatally acquired HIV who would other-
wise have died in infancy and early childhood are now
reaching adolescence in large numbers due to earlier diagno-
sis, treatment initiation and the global scale-up of antiretro-
viral therapy (ART) [10]. At least a third of HIV-infected
infants have slow progressing disease, with a median survival
of at least 16 years [11,12]. Many children infected a dec-
ade or so ago before PMTCT programmes were available
therefore present to health services for the first time in
adolescence [1].
While the rate of new infections among adults has stabilized
in many countries, the decline in the incidence of infection
among adolescents and young people has been slower. A third
of new infections occur in the 15–24 year age group, with an
estimated 670,000 young people in this age group newly
infected with HIV in 2015, representing over 40% of new HIV
infections globally [13]; of these, 250,000 were adolescents
aged 15–19 years old [8].
This growing cohort of adolescents presents a challenge to
resource-limited health services not used to effectively manag-
ing adolescents, a subset of whom have complex treatment
histories and chronic illness [10].
3 | ADOLESCENTS AND TREATMENT
OUTCOMES
Adolescence is a period of physiological and psychological
growth characterized by biological, sexual and identity devel-
opment and increasing social autonomy [14,15]. This stage of
development is a high-risk period in terms of engagement
with healthcare services, as adolescents often experience
destabilizing socio-cultural change coupled with increased risk-
taking behaviour and decreased parental support [16]. Poor
adherence to treatment during adolescence has been
reported for many chronic conditions, including diabetes,
asthma and epilepsy [16]. HIV is no exception, and adolescents
living with HIV are not only less likely to initiate ART than
adults, but those who do start ART are less likely to remain in
care and adhere to treatment [17]. Intermittent medication
adherence increases the risk of treatment failure and subse-
quent development of drug resistance [18,19]. Studies in high-
and low-resource settings have shown that adolescents have
worse virological outcomes than other age groups [20–22].
Those with chronic conditions may be more impacted by the
risk-taking behaviours that characterize adolescence than their
peers without chronic medical problems in terms of impact on
their health and ability to manage their illness [23,24]. Living
with chronic disease can result in considerable psychological
burden, involving social and educational disruption, real or
perceived stigma, and the difficulties of adjusting to adult
healthcare services as they transition from paediatric care
[25]. In addition, particularly those adolescents with perinatally
acquired infection may have lost one or both parents to HIV,
with significant economic, social and psychological conse-
quences and adverse impacts on treatment access and health
outcomes [26].
Both adolescents with perinatally acquired and non-perina-
tally acquired HIV have varied and overlapping risk factors for
treatment failure and subsequent development of drug resis-
tance. Adolescents in both groups face the complexities of liv-
ing with an oft-stigmatized condition throughout adolescence
and into adulthood with the attendant risks on adherence and
retention in care.
Adolescents with perinatally acquired HIV are at high risk
for treatment failure and multiclass drug resistance for several
reasons. Those who have reached adolescence are likely to
have had exposure to ART to prevent perinatal HIV infection
or started ART early in life, and may be heavily treatment
experienced [27,28]. Subtherapeutic drug concentrations
caused by limited paediatric drug formulations, variable phar-
macokinetics and physiological changes may increase the risk
of drug-resistant virus with subsequent virologic failure [29–
31]. Many perinatally infected adolescents today would have
started ART early in life in a time when triple ART regimens
were unavailable [1]. Mono- or dual therapy regimens may
have resulted in incomplete viral suppression and the emer-
gence of drug-resistant virus [32–34]. In a European multicen-
tre paediatric HIV cohort, 25% had triple-class failure after
8 years on ART [34], and in LMICs, multiclass drug resistance
of up to 90% has been demonstrated in perinatally infected
children and adolescents [20,27,35]. In the absence of VL test-
ing, detection of treatment failure may be delayed and
patients may be maintained on inadequate and subtherapeutic
treatment, with subsequent increased risk of development of
drug resistance [36]. The consequences of drug-resistant virus
and treatment failure may have life limiting consequences in
children and adolescents who will require treatment for many
years longer than adults.
Adolescents with recently acquired HIV infection are also at
substantial risk of treatment failure and drug resistance
[37,38]. HIV acquisition in adolescence is often associated
with high-risk sexual behaviour including low rates of condom
use, multiple concurrent partners, transgenerational and trans-
actional sex [39]. In sub-Saharan Africa, adolescent girls have
a four times higher prevalence of HIV than their male coun-
terparts [4]. Adolescents from key populations, including men
who have sex with men (MSM), transgender people, injecting
drug users and commercial sex workers have a particularly
high HIV prevalence [4]. Available data suggest that young
MSM often have a higher risk of acquiring HIV than hetero-
sexual young men or older MSM, with prevalence rates of
between 3% and 24% reported across a diverse range of set-
tings in 10–24 year olds [40]. The risk factors and social con-
ditions that lead to HIV acquisition in adolescence may
subsequently impact on their ability to engage in care, with
the attendant risks of treatment failure [41]. Sexual risk beha-
viours and subsequent HIV risk in adolescents are also subject
to stigmatization [39,42]. HIV-related stigma in youth corre-
lates with factors that threaten ART adherence with an
increased potential for developing drug-resistant virus [43–
45]. Data from the USA reports a high prevalence of geno-
typic and phenotypic drug resistance in newly infected youth
[37,38] and more data is emerging from LMICs on the rising
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prevalence of transmitted drug resistance in newly infected
adolescents and adults [46,47].
4 | THE CASE FOR VIRAL LOAD
MONITORING FOR ADOLESCENTS
Viral load testing is recommended by the WHO as the gold
standard for monitoring HIV treatment and failure in all
patients [48]. In high-income countries, HIV VL testing is rou-
tinely used for monitoring patients on ART, whereas in
resource-limited settings, clinical and immunologic (CD4
count) monitoring is largely used to diagnose treatment failure
[49]. It is recognized that this approach is inadequate for
treatment monitoring as clinical or immunological monitoring
delays recognition of virological failure with potential accumu-
lation of drug resistance mutations and a subsequent reduc-
tion in future treatment options [50]. It may also lead to
unnecessary switching to second-line therapy in those with
suspected poor adherence, for example in those whose CD4
counts have not fully reconstituted since ART initiation or in
those who develop an opportunistic infection but are in fact
virologically suppressed [51,52].
VL monitoring is not available in most resource-limited set-
tings [1,27,50]. While all populations living with HIV would
benefit from the scale-up of VL testing, VL roll-out could ini-
tially be targeted at certain high-risk populations especially
vulnerable to virological failure such as during adolescence, a
period when maintaining sustained adherence to treatment
and engagement with care is particularly challenging [13,53].
Although universal VL monitoring in LMIC may not be cost-
effective while costs of VL testing remain high, selecting key
populations at risk of poor adherence might allow for more
efficient use of resources by identifying those with an unde-
tectable VL for whom less intensive differentiated care
options are more appropriate, and highlighting those individu-
als who need more intensive support [54].
Adolescence is also a period of increased sexual risk taking
with subsequent risk of both HIV acquisition and transmission
and of unplanned pregnancy [55,56]. VL monitoring will allow
those who not virologically suppressed to be identified,
thereby allowing targeted adherence interventions to reduce
onward sexual and vertical transmission. Young people begin
to assert more autonomous control over their decisions dur-
ing adolescence [14]. Chronic illness can engender a feeling of
powerlessness amongst adolescents, who may then choose to
exercise control by not taking medication, or attending
appointments for example [57]. Using VL testing as a defini-
tive marker of treatment outcomes may allow for active ado-
lescent participation in tracking self-progress.
As adolescents with perinatally acquired HIV may be heavily
treatment experienced and on second or even third-line ther-
apy, and both those with perinatally acquired HIV and newly
infected adolescents may have suboptimal treatment adher-
ence, VL testing in this age group would allow clinicians to
make informed decisions about increased counselling and sup-
port for adolescents together with the need to maintain or
switch therapeutic regimens. VL monitoring accompanied by
appropriate regimen change will reduce the time spent on a
failing regimen avoiding the selection of resistant viral muta-
tions [58]. This is of particular importance in adolescents with
perinatally acquired HIV, who often have a history of inade-
quate viral suppression. Even without widespread availability
of genotypic resistance testing, VL monitoring would give clini-
cians an important decision-making tool that will impact an
adolescent’s treatment options for many years.
In low- and middle-income countries where limited VL test-
ing is available, measuring VL six months after treatment initi-
ation gives healthcare professionals the opportunity to
intervene with targeted adherence and support interventions
[52,59]. Risk factors such as poor adherence, female gender,
high baseline VL and non-nucleoside reverse transcriptase
inhibitor (NNRTI) based-regimes have been associated with
virological failure among adolescents [27,34]. Preservation of
ART regimens is important in an adolescent population who
will require ART for longer than adults. Given that adolescents
are at higher risk of treatment failure when compared with
adults, targeting VL testing at certain adolescent subgroups at
high risk of failure may increase the yield of detecting treat-
ment failure and make regime choices more efficient.
5 | OPPORTUNITIES FOR DEVELOPING
VL MONITORING FOR ADOLESCENTS
Adolescents are a mobile group, with migration linked to key
transitions into adulthood, for example from rural to urban
areas for employment or educational opportunities [60].
Engaging and retaining these populations in care using tradi-
tional healthcare facilities is challenging, and innovative and
adolescent-responsive differentiated models of HIV care may
improve outcomes across the HIV care continuum [61]. Point-
of-care (POC) technology may be particularly beneficial in tar-
geting adolescents as part of a hard-to-reach-group [62].
Although cost of POC technology is currently prohibitive for
widespread roll-out in low-resource settings, research and
development for a semiquantitative POC VL assay is in pro-
gress [63]. Near-patient VL testing technology could be incor-
porated into mobile health clinics for example, which use rapid
and near-patient technologies for HIV testing and CD4 count
monitoring to engage hard-to-reach adolescent populations in
care [62]. Flexible methods of VL testing including decentral-
ized and near-patient VL testing with rapid availability of
results will allow clinicians to make prompt decisions about
treatment failure or the need for regime change, and may
obviate need for repeated clinic visits thereby reducing educa-
tional, employment and social disruption. Blood obtained from
a finger prick with results read from a test strip, much like a
POC HIV test, would remove the need for phlebotomists or
centrifugation and may be more acceptable to adolescents
than venesection [64]. One such POC VL system has received
regulatory approval in Malawi, and product approval in
Uganda and Kenya, but has not been validated for paediatric
or adolescent use [63].
Phased implementation of VL testing would allow logistical
and technical capacity-building for universal access in a con-
text where introduction of routine VL monitoring for the gen-
eral population living with HIV is not feasible. Initial
implementation of VL assays in LMICs could prioritize groups
such as adolescents who are at higher risk of treatment fail-
ure and constitute a smaller group compared to adults with
HIV. Initiating VL testing in adolescents as a sub-section of
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the population living with HIV could provide a platform for
investigating the feasibility, cost-effectiveness, and acceptabil-
ity of VL testing in these settings, with the potential to inform
wider scale implementation.
6 | CONCLUSIONS
The impact of global ART programme scale-up has produced
astounding gains in mortality, turning an inevitably fatal condi-
tion into a chronic disease requiring lifelong treatment with
sustained adherence. The Global Plan for the eradication of
vertical transmission of HIV has significantly reduced the num-
ber of children born with HIV. Early diagnosis and treatment
has resulted in most of these children reaching adolescence.
The global community set the goal of ending the HIV epidemic
by 2030, with ambitious targets to get 90% of people with
HIV tested, 90% of those tested on treatment and 90% of
those on treatment virally suppressed. Yet in 2016, we saw
almost 2 million new HIV infections, most of those in adoles-
cents and young people. As universal ‘test-and-treat’ becomes
reality, the numbers initiating ART will rise. One group who
will continue to pose significant treatment challenges are ado-
lescents either graduating from paediatric care or newly
established on ART treatment who may encounter treatment
fatigue with an associated risk of failure. Unlike in the early
days of ART where saving lives was the primary objective, we
are entering a phase where VL testing is essential in order to
successfully maintain people on long-term ART to ensure the
promise of universal treatment scale-up. VL testing scale-up is
critical in all groups, yet, focusing on adolescents for initial
operational research and scale-up will allow targeted investi-
gation into optimum ways of integrating VL monitoring into
differentiated models of care, cost-effectiveness and evaluat-
ing how this cost can be weighed against other HIV preven-
tion and care programme priorities for this vulnerable group.
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